微创心通-B(02160.HK) 公布,国家药品监督管理局医疗器械技术审评中心发布审查结果公示,拟同意集团旗下新一代植入式心律转复除颤器“ICD”TILEN/EYLEN进入创新医疗器械特别审查程序。据此,TILEN/EYLEN有望成为国内首款获批的具备自主知识产权的磁共振条件安全ICD。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-13 16:25。)AASTOCKS新闻
Source Link微创心通-B(02160.HK) 公布,国家药品监督管理局医疗器械技术审评中心发布审查结果公示,拟同意集团旗下新一代植入式心律转复除颤器“ICD”TILEN/EYLEN进入创新医疗器械特别审查程序。据此,TILEN/EYLEN有望成为国内首款获批的具备自主知识产权的磁共振条件安全ICD。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2026-02-13 16:25。)AASTOCKS新闻
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.